Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Frontage Holdings Corp. ( (HK:1521) ) has issued an update.
Frontage Holdings Corporation announced its unaudited financial results for the third quarter of 2025, reporting a slight revenue increase to approximately US$191.4 million for the nine months ending September 30, 2025. The company’s net profit saw a significant rise to US$5.6 million, compared to US$0.2 million in the same period in 2024, with an adjusted net profit increase of 32.5% to US$12.6 million. The announcement highlights the company’s improved financial performance, which may positively impact its market position and investor confidence.
The most recent analyst rating on (HK:1521) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Frontage Holdings Corp. stock, see the HK:1521 Stock Forecast page.
More about Frontage Holdings Corp.
Frontage Holdings Corporation, incorporated in the Cayman Islands, operates in the pharmaceutical and biotechnology industry. The company focuses on providing drug development services, including laboratory and clinical research services, to pharmaceutical and biotech companies.
Average Trading Volume: 480,698
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.22B
For an in-depth examination of 1521 stock, go to TipRanks’ Overview page.